Home » Drug Information » FDA-Approved Drugs » 1997
Medical Areas: Neurology
View By: Year Company Therapeutic Areas Drug Names
Drug Information
The following information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: GlaxoSmithKline
Approval Status: Approved August 1997
Treatment Area: migraine headaches
Glaxo Wellcome, Inc. has received clearance from the FDA to
market the nasal spray form of Imitrex (sumatriptan). Imitrex is
the company's innovative therapy for the acute treatment of
migraine and is currently available in the U.S. in subcutaneous
injection form and tablet form. Imitrex Nasal Spray will be
available to consumers by prescription in October.
In clinical trials for Imitrex Nasal Spray 20 mg, the most
common side effects included bad/unusual taste, and nausea and/or
vomiting. Most side effects are mild and transient.
Imitrex, a nonsedating, nonnarcotic medication, is the only
migraine therapy that treats the multiple symptoms characteristic
of migraine, including severe recurrent pain usually on one side of
the head often accompanied by one or more of the following: nausea,
and sensitivity to light and sound. Imitrex is equally effective
when taken at any point during a migraine headache.
